Benzbromarone is an inhibitor of the urate anion transporter (IC50 = 0.3 μM for hURAT1) that prevents renal urate resorption. It also potently inhibits CYP2C9 (Ki = 20 nM), a major cytochrome P450 enzyme involved in the metabolic clearance of a wide range of therapeutic agents. Several analogs of benzabromarone have been developed with varying binding affinities to CYP2C9 in order to study adverse drug-drug interactions.
